Michael Ashby
5PUBLICATIONS
13CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jul 29, 2025
Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.Rithin Nedumannil, Michael Ashby, James Rowland
|Mar 08, 2025
Filling the gaps to empower regional centres to manage myelodysplastic syndrome and acute myeloid leukaemia leading to wider cancer healthcare delivery and access to clinical trials.Michael Ashby, Shaun Fleming, Andrew Spencer
|Jan 18, 2025
Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT).Chong Chyn Chua, Sun Loo, Chun Yew Fong
|Mar 01, 2024
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).Ing Soo Tiong, Devendra K Hiwase, Emad Abro
|Jul 18, 2022
Spheroacanthocytes secondary to novel tyrosine kinase inhibitors.Michael Ashby, Michael Sze Yuan Low
Pageof 1
Frequent Collaborators
3 joint publications
John Reynolds
3 joint publications
Sun Loo
3 joint publications
Andrew H Wei
2 joint publications
Ing Soo Tiong
2 joint publications
Natasha S Anstee
2 joint publications
Chun Yew Fong
1 joint publications
Ashish Bajel
1 joint publications
Chong Chyn Chua
1 joint publications
Richard Dillon
1 joint publications
Stephen B Ting
